Treatment of toenail onychomycosis
Austad, J.; Gjersvik, P.J.
Tidsskrift for den Norske Laegeforening Tidsskrift for Praktisk Medicin Ny Raekke 121(5): 606-607
2001
ISSN/ISBN: 0029-2001 PMID: 11301619 Document Number: 534298
Document emailed within 1 workday
Related Documents
Bonhert, K.; Dorizas, A.; Sadick, N.S. 2019: Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd:YAG laser for treatment of toenail onychomycosis Journal of Cosmetic and Laser Therapy 21(3): 179-183Tschen, E.H.; Bucko, A.D.; Oizumi, N.; Kawabata, H.; Olin, J.T.; Pillai, R. 2013: Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study Journal of Drugs in Dermatology: Jdd 12(2): 186-192
Epstein, E. 1998: How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data Archives of Dermatology 134(12): 1551-1554
Hofmann, H.; Bräutigam, M.; Weidinger, G.; Zaun, H. 1995: Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group Archives of Dermatology 131(8): 919-922
Assadamongkol, R.; Lertwattanarak, R.; Wannachalee, T.; Bunyaratavej, S.; Leeyaphan, C.; Matthapan, L. 2016: Prevalence, Risk Factors, and Type of Organism in Fungal Foot Infection and Toenail Onychomycosis in Thai Diabetic Patients Journal of the Medical Association of Thailand 99(6): 659-664
Petrushenko, N.I. 1984: Ingrown toenail and its conservative treatment Fel'dsher i Akusherka 49(1): 60-62
Navrátil, K.; Romanov, V. 2005: Modification of surgical treatment of ingrowing toenail Rozhledy V Chirurgii: Mesicnik Ceskoslovenske Chirurgicke Spolecnosti 84(8): 426-429
Shemer, A.; Bergman, R.; Cohen, A.; Friedman-Birnbaum, R. 1992: Treatment of onychomycosis using 40% urea with 1% bifonazole Harefuah 122(3): 159-160
El Euch, D.; Bouassida, S.; Kourda, M.; Ezzine, N.; Denguezli, M.; Mokhtar, I.ça.; Doss, N.; Turki, H.; Ridha Kamoun, M.; Nouira, R.; Ben Osman Dhahril, A. 2006: Fluconazole and treatment of onychomycosis. about 86 cases La Tunisie Medicale 84(10): 640-643
Hanna, S.; Andriessen, A.; Beecker, J.; Gilbert, M.; Goldstein, E.; Kalia, S.; King, A.; Kraft, J.; Lynde, C.; Singh, D.; Turchin, I.; Zip, C. 2018: Clinical Insights About Onychomycosis and Its Treatment: A Consensus Journal of Drugs in Dermatology: Jdd 17(3): 253-262
Dominguez-Cherit, J.; Teixeira, F.; Arenas, R. 1999: Combined surgical and systemic treatment of onychomycosis British Journal of Dermatology 140(4): 778-780
Ershov, V.P. 1984: Use of sombrevin and ketalar in the surgical treatment of onychomycosis Voenno-Meditsinskii Zhurnal 1984(6): 50
Nasir, A.; Goldstein, B.; van Cleeff, M.; Swick, L. 2011: Clinical evaluation of safety and efficacy of a new topical treatment for onychomycosis Journal of Drugs in Dermatology: Jdd 10(10): 1186-1191
Del Rosso, J.Q. 1996: Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy Journal of the American Osteopathic Association 96(10): 607-609
Elewski, B.E.; Cantrell, W.; Lin, T. 2018: Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis? Journal of Drugs in Dermatology: Jdd 17(2): 175-178
Daniel, R.C. 2013: Onychomycosis: burden of disease and the role of topical antifungal treatment Journal of Drugs in Dermatology: Jdd 12(11): 1263-1266
Maddin, S.; Quiring, J.; Bulger, L. 2013: Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis Journal of Drugs in Dermatology: Jdd 12(7): 758-763
Gupta, A.K.; Ryder, J.E.; Lynch, L.E.; Tavakkol, A. 2005: The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence Journal of Drugs in Dermatology: Jdd 4(3): 302-308
Galitz, J. 2001: Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report Cutis 68(2 Suppl): 23-24
Aly, R.; Winter, T.; Hall, S.; Vlahovic, T. 2018: Topical Tavaborole in the Treatment of Onychomycosis Complicated by Dermatophytoma: a Post-hoc Assessment of Phase Ii Subjects Journal of Drugs in Dermatology: Jdd 17(3): 347-354